// App-Quantinova.ai

: Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK

Researchers

Presenter

  • Nicolas Roche

Principal Investigators

  • Hicham Benhaddi

  • Marianka van der Tol

  • Jonathan Chambers

  • Job FM van Boven

  • Leif Bjermer

  • Marc miravitlles

  • David Price

  • Jaco Voorham

Medical Centers

  • Hopitaux Universitaires Paris-Sud, Paris, France

  • Teva Pharmaceuticals Europe B.V., Brussels, Belgium

  • Teva Pharmaceuticals, Amsterdam, Netherlands,

  • Teva Pharmaceuticals Europe B.V., Winchester, United Kingdom

  • GRIAC (Groningen Research Institute for Asthma and COPD), University Medical Center Groningen, University of Groningen, Groningen, Netherlands,

  • Lund University Hospital, Lund, Sweden

  • Hospital Universitario del Mar, Barcelona, Spain

  • Observational and Pragmatic Research Institute, Singapore, Singapore,

Locations

  • France

  • Belgium

  • Netherlands

  • United Kingdom

  • Sweden

  • Spain

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • budesonide + formoterol fuma

  • DuoResp Spiromax

  • Budesonide

  • Formoterol

  • Symbicort

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved